Expert view: Are you ready for next generation therapeutic antibodies?
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
The biotherapeutics landscape is moving fast towards molecules with higher potency and greater efficiency than ever before. The rise and growth of bispecific antibodies (bsAbs) has fuelled this move; mainly due to their capability of binding to two antigens at the same time, thereby increasing therapeutic efficacy and decreasing the need for large production volumes. However, with about 100 different formats of bsAb currently under development, selecting, analysing and purifying the best candidate for therapeutic drug development presents multiple challenges.